Intradermal vaccination using the novel microneedle device MicronJet600: Past, present, and future

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 4, 2015, Pages 991-997

  Levin, Yotam ^a   Kochba, Efrat ^a   Hung, Ivan ^b   Kenney, Richard ^c  

^a NANOPASS TECHNOLOGIES LTD   (Israel)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

^c Immune Design Corp   (United States)

Author keywords

Dose sparing; Immunogenicity; Influenza vaccine; Intradermal; Mantoux; Microneedles; Vaccine delivery; Vaccine device

Indexed keywords

BCG VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; RABIES VACCINE; VACCINE; VARICELLA ZOSTER VACCINE;

ARTHRALGIA; ARTICLE; COMPARATIVE STUDY; DEVICE SAFETY; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; EDEMA; ERYTHEMA; FEVER; HUMAN; IMMUNOGENICITY; INFLUENZA; META ANALYSIS (TOPIC); MICRONEEDLE; MICRONJET600; MYALGIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RABIES; TUBERCULIN TEST; VACCINATION; INTRADERMAL DRUG ADMINISTRATION; PROCEDURES; TRENDS;

HUMANS; INFLUENZA VACCINES; INJECTIONS, INTRADERMAL; VACCINATION;

EID: 84938772003     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1010871     Document Type: Article

References (120)

1. Gross CP, Sepkowitz KA. The myth of the medical breakthrough: Smallpox, vaccination, and Jenner reconsidered. IJID 1998; 3:54-60; PMID:9831677. http://www. ijidonline. com/article/S1201-9712(98) 90096-0/pdf
2. Millar JD, Foege W. H. Status of eradication of smallpox (and control of measles) in West and Central Africa. J Infect Dis 1969; 120:725-32; PMID:5374972; http://dx. doi. org/10. 1093/infdis/ 120. 6. 725
3. Jenner E. An Inquiry into the Causes and Effects of the Variolae Vaccinae: A Disease Discovered in Some of the Western Counties of England, Particularly Gloucestershire, and Known by the Name of the Cow Pox. London: Sampson Low; 1798, 1-2
4. Jenner E. Two cases of small-pox infection communicated to the foetus in utero under peculiar circumstances, with additional remarks. Med Chir Trans 1809; 1:271-7; PMID:20895118. http://www. ncbi. nlm. nih. gov/pmc/articles/PMC2128795/pdf/medcht00073- 0301. pdf
5. Payette PJ, Davis HL. History of vaccines and positioning of current trends. Curr Drug Targets Infect Disord 2001; 1:241; PMID:12455398; http://dx. doi. org/10. 2174/1568005014606017
6. Jenner E, Razzell PE. The history of a medical myth. Med Hist 1965; 9:216-29. http://www. ncbi. nlm. nih. gov/pmc/articles/PMC1033502/pdf/medhist00154- 0020. pdf
7. Calmette A. Preventive vaccination against tuberculosis with BCG. Proc R Soc Med 1931; 24:1481. http:// www. ncbi. nlm. nih. gov/pmc/articles/PMC2182232/ pdf/procrsmed00808-0023. pdf
8. Mantoux C. L'intradermo-reaction a la tuberculine et son interpretation clinique. Presse Med 1910; 18:10-3
9. Flynn PM, Shenep JL, Mao L, Crawford R, Williams BF, Williams BG. Influence of needle gauge in Mantoux skin testing. Chest 1994; 106:1463-65; PMID:7956403; http://dx. doi. org/10. 1378/ chest. 106. 5. 1463
10. Tarnow K, King N. Intradermal injections: traditional bevel up versus bevel down. ANR 2004; 17:275-82; PMID:15573336; http://dx. doi. org/10. 1016/j. apnr. 2004. 09. 009
11. Lambert PH, Laurent PE. Intradermal vaccine delivery: Will new delivery systems transform vaccine administration? Vaccine 2008; 26:3197-208; PMID:18486285; http://dx. doi. org/10. 1016/j. vaccine. 2008. 03. 095
12. Dacso CC. Skin Testing for Tuberculosis. In: Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd edition. Boston: Butterworths; 1990. Chapter 47. Available from: http://www. ncbi. nlm. nih. gov/books/ NBK369/
13. Salisbury DM, Begg NT(Eds.). 1996. Immunisation against infectious disease: the green book. Department of Health, London.
14. Frösner G, Steffen R, Herzog C. Virosomal hepatitis A vaccine: Comparing intradermal and subcutaneous with intramuscular administration. J Travel Med 2009; 16:413-9; PMID:19930383; http://dx. doi. org/ 10. 1111/j. 1708-8305. 2009. 00351. x
15. Pancharoen C, Mekmullica J, Thisyakorn U, Kasempimolporn S, Wilde H, Herzog C. Reduced-dose intradermal vaccination against hepatitis A with an aluminum-free vaccine is immunogenic and can lower costs. CID 2005; 41:1537-40; PMID:16231271; http://dx. doi. org/10. 1086/497266
16. Chen W, Gluud C. Vaccines for preventing hepatitis B in health-care workers. Cochrane Database of Systematic Reviews 2005; Issue 4. Art. No.: CD000100. DOI: 10. 1002/14651858. CD000100. pub3
17. Sangare L, Manhart L, Zehrung D, Wang CC. Intradermal hepatitis B vaccination: A systematic review and meta-analysis. Vaccine 2009; 27:1777-86; http:// dx. doi. org/10. 1016/j. vaccine. 2009. 01. 043
18. Braddick MR. Intradermal hepatitis B vaccine. Lancet 1989; 1:957-8; http://dx. doi. org/10. 1016/S0140- 6736(89)92533-6
19. Redfield RR, Innis BL, Scott RM, Cannon HG, Bancroft WH. Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine-A cost reduction strategy. JAMA 1985; 254:3203-6; PMID:2933535; http://dx. doi. org/10. 1001/ jama. 1985. 03360220069031
20. Wistrom J. Intramuscular vs. intradermal hepatitis B vaccination: A 6-year follow-up. JAMA 1995; 273:1835-6; PMID:7776497; http://dx. doi. org/ 10. 1001/jama. 1995. 03520470043027
21. Kyi KP, Oo KM, Htun MM, Tun WM, Aye KK, Oo SS, Lwin KO, Nyunt S. Clinical trial of the intradermal administration of hepatitis B vaccine produced at the Department of Medical Research, Myanmar. Vaccine 2002; 20:1649-52; PMID:11858874; http://dx. doi. org/10. 1016/S0264-410X(01)00468-6
22. Fishbein DB, Pacer RE, Holmes DF, Ley AB, Yager P, Tong TC. Rabies pre exposure prophylaxis with human diploid cell rabies vaccine: A dose-response study. J Infect Dis 1987; 156:50-5; http://dx. doi. org/ 10. 1093/infdis/156. 1. 50
23. Warrell MJ, Warrell DA, Nicholson KG, Suntharasamai P, Chanthavanich P, Viravan C, Udomsakdi D. Economical multiple-site intradermal immunisation with human diploid-cell-strain vaccine is effective for post-exposure rabies prophylaxis. Lancet 1985; 325:1059-62; PMID:2860284; http://dx. doi. org/ 10. 1016/S0140-6736(85)92367-0
24. Quimbao BP, Dimaano EM, Ambas C, Davis R, Banzhoff A, Malerczyk C. Reducing the cost of postexposure rabies prophylaxis: Efficacy of 0. 1 ml PCEC rabies vaccine administered intradermally using the Thai Red Cross post-exposure regimen in patients severely exposed to laboratory-confirmed rabid animals. Vaccine 2005; 23:1709-14; PMID:15705476; http://dx. doi. org/10. 1016/j. vaccine. 2004. 09. 027
25. Khawplod P, Wilde H, Sirikwin S, Benjawonqkulchai M, Limusanno S, Jaijaroensab W, Chiraguna N, Supich C, Wangroongsarb Y, Sitprija V. Revision of the Thai Red Cross intradermal rabies post-exposure regimen by eliminating the 90-day booster injection. Vaccine 2006; 24:3084-6; PMID:16494972; http:// dx. doi. org/10. 1016/j. vaccine. 2006. 01. 051
26. World Health Organization. Rabies vaccines. WHO position paper. Wkly Epi demiol Rec 2010; 85:309-20. http://www. who. int/wer/2010/wer8532. pdf?ua=1
27. Hung IF, Levin Y, To KK. Quantitative and qualitative analysis of antibody response after dose sparing intradermal 2009 H1N1 vaccination. Vaccine 2012; 30:707-2708; PMID:22210225; http://dx. doi. org/ 10. 1016/j. vaccine. 2011. 12. 069
28. Whittle HC, Rowland MG, Mann GF, Lamb WH, Lewis RA. Immunisation of 4-6 month old Gambian infants with Edmonston-Zagreb measles vaccine. Lancet 1984; 2:834-7; PMID:6148572; http://dx. doi. org/10. 1016/S0140-6736(84)90873-0
29. Edens C, Collins ML, Ayers J, Rota PA, Prausnit MR. Measles vaccination using a microneedle patch. Vaccine 2013; 31:3403-9; PMID:23044406; http://dx. doi. org/10. 1016/j. vaccine. 2012. 09. 062
30. Burland WL. Measles vaccination by the intradermal route. Postgrad Med J 1969; 45:323-6; http://dx. doi. org/10. 1136/pgmj. 45. 523. 323
31. Icardi G, Orsi A, Ceravolo A, Ansaldi F. Current evidence on intradermal influenza vaccines administered by SoluviaTM licensed micro injection system. Hum Vaccin Immunother 2012; 8:67-75; PMID:22293531; http://dx. doi. org/10. 4161/ hv. 8. 1. 18419
32. Arnou R, Eavis P, Pardo JR, Ambrozaitis A, Kazek MP, Weber F. Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years: Randomized, controlled, phase III trial. Hum Vaccine 2010; 6:346-54; PMID:20372053; http://dx. doi. org/10. 4161/ hv. 6. 4. 10961
33. Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon O, Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 2009; 27:454-9; PMID:19022318; http://dx. doi. org/10. 1016/j. vaccine. 2008. 10. 077
34. Belshe RB, Newman FK, Wilkins K, Graham IL, Babusis E, Ewell M, Frey SE. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 2007; 25:6755-63
35. Tsang P, Gorse GJ, Strout CB, Sperling M, Greenberg DP, Ozol-Godfrey A, Diaz-Granados C, Landolfi V. Immunogenicity and safety of Fluzone® intradermal and high-dose influenza vaccines in older adults ≥65 years of age: A randomized, controlled, phase II trial. Vaccine 2014; 32:2507-17; PMID:24120672; http://dx. doi. org/10. 1016/j. vaccine. 2013. 09. 074
36. Levin Y, Kochba E, Kenney R. Clinical evaluation of a novel microneedle device for intradermal delivery of an influenza vaccine: Are all delivery methods the same? Vaccine 2014; 32:4249-52; PMID:24930715; http://dx. doi. org/10. 1016/j. vaccine. 2014. 03. 024
37. Roukens AH, Vossen AC, Bredenbeek PJ, Van Dissel JT, Visser LG. Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial. PLoS One 2008; 3:e1993; PMID:18431480; http://dx. doi. org/10. 1371/journal. pone. 0001993
38. Roukens AH, Vossen AC, Van Dissel JT, Visser LG. Reduced intradermal test dose 240 of yellow fever vaccine induces protective immunity in individuals with egg 241 allergy. Vaccine 2009; 27:2408-9; PMID:19368780; http://dx. doi. org/10. 1016/j. vaccine. 2009. 02. 049
39. Hickling J, Jones R. Yellow fever vaccination: The potential of dose-sparing to increase vaccine supply and availability. PATH report. April 18, 2013. http:// www. path. org/publications/files/TS_vtg_yf_rpt. pdf. Retrieved August 1st, 2014
40. Mohammed AJ, AlAwaidy S, Bawikar S, Kurup PJ, Elamir E, Shaban M, Sharif SM, Van Der Avoort H, Pallansch MA, Malankar P, et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med 2010; 362:2351-9; PMID:20573923; http://dx. doi. org/10. 1056/NEJMoa0909383
41. Resik S, Tejeda A, Lago PM, Diaz M, Carmenates A, Sarmiento L, Alemañi N, Galindo B, Burton A, Friede M, et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis 2010; 201:1344-52; PMID:20350164; http://dx. doi. org/10. 1086/651611
42. Nirmal S, Cherian T, Samuel BU, Rajasinght J, Raghupathy P, Jacob JT. Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine. Vaccine 1998; 16:928-31; http://dx. doi. org/10. 1016/S0264-410X(97)00293-4
43. Estívariz CF, Jafari H, Sutter RW, John TJ, Jain V, Agarwal A, Verma H, Pallansch MA, Singh AP, Guirguis S, et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: A community-based, randomised controlled trial. Lancet Infect Dis 2012; 12:128-35; PMID:22071249; http://dx. doi. org/10. 1016/S1473- 3099(11)70190-6
44. Zoulek G, Roggendorf M, Deinhardt F, Kunz C. Different immune responses after intradermal and intramuscular administration of vaccine against tick borne encephalitis virus. J Med Virol 1986; 19:55-61; PMID:3701303; http://dx. doi. org/10. 1002/ jmv. 1890190109
45. Baxby D. Smallpox vaccination techniques; from knives and forks to needles and pins. Vaccine 2002; 20:2140-9; PMID:11972983; http://dx. doi. org/ 10. 1016/S0264-410X(02)00028-2
46. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004; 351:2295-301; PMID:15525714; http://dx. doi. org/10. 1056/ NEJMoa043540
47. Brown LE. The role of adjuvants in vaccines for seasonal and pandemic influenza. Vaccine 2010; 28:8043-5; http://dx. doi. org/10. 1016/j. vaccine. 2010. 09. 024
48. Nordin J, Mullooly J, Poblete S, Strikas R, Petrucci R, Wei F, Rush B, Safirstein B, Wheeler D, Nichol KL. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: Data from 3 health plans. J Infect Dis 2001; 184:665-70; http:// dx. doi. org/10. 1086/323085
49. Gill HS, Kang SM, Quan FS, Compans RW. Cutaneous immunization: An evolving paradigm in influenza vaccines. Expert Opin Drug Deliv 2014; 11:615-27; PMID:24521050; http://dx. doi. org/10. 1517/ 17425247. 2014. 885947
50. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 331:778-84; PMID:8065407; http://dx. doi. org/10. 1056/ NEJM199409223311206
51. Resik S, Tejeda A, Sutter RW, Diaz M, Sarmiento L, Alemañi N, Aylward RB. Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med 2013; 368:416-24; PMID:23363495; http://dx. doi. org/10. 1056/NEJMoa1202541
52. Hickling J, Jones R, Nundy N. Improving the affordability of inactivated poliovirus vaccines (IPV) for use in low-and middle-income countries: PATH (Program for Appropriate Technology in Health), 2010. http://www. path. org/publications/files/TS_IPV_eco n_analysis. pdf
53. Meeting of the Strategic Advisory Group of Experts on immunization, April 2012--Conclusions and recommendations. 25 May 2012, vol. 87, 21 (pp 201- 16). http://www. who. int/wer. Retrieved on August 1, 2014
54. Polio Eradication and Endgame Strategic Plan 2013-2018. http://www. polioeradication. org/resourcelibrary/ strategyandwork. aspx#sthash. IF1yZB1Z. Retrieved on August 1, 2014
55. Zehrung D Kristensen D. Intradermal Delivery of Vaccines: A Review of the Literature and the Potential for Development for Use in Low- and Middle-Income Countries. August 27, 2009 http://www. path. org/pub lications/detail. php?i=1746.
56. Tuft L. The skin as an immunological organ with results of experimental investigations and review of the literature. J Immunol 1931; 21:85-100. http:// www. jimmunol. org/content/21/2/85. abstract
57. Francis T, Magill TP. The antibody response of human subjects vaccinated with the virus of human influenza. J Exp Med 1937; 65:251-9; PMID:19870599; http://dx. doi. org/10. 1084/ jem. 65. 2. 251
58. Fluzone Prescribing Information". Sanofi Pasteur. April 2013
59. World Health Organization: WHO recommendations on rabies post-exposure treatment and the correct technique of intradermal immunization against rabies. WHO/EMC/ZOO. 96. 6. 1997. http://whqlib doc. who. int/hq/1996/WHO_EMC_ZOO_96. 6. pdf
60. Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, Karrasch J, McKeirnan M, Salem H, Mills G, Reid J, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: A randomized controlled trial. J Infect Dis 2008; 198:650-8; PMID:18652550; http://dx. doi. org/ 10. 1086/590434
61. Laurent PE, Bonnet S, Alchas P, Regolini P, Mikszta JA, Pettis R, Harvey NG. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 2007; 25:8833-42; PMID:18023942; http://dx. doi. org/10. 1016/j. vaccine. 2007. 10. 020
62. Arnou R, Icardi G, De Decker M, Ambrozaitis A, Kazek MP, Weber F, Van Damme P. Intradermal influenza vaccine for older adults: A randomized controlled multicenter phase III study. Vaccine 2009; 27:7304-12; PMID:19849996; http://dx. doi. org/ 10. 1016/j. vaccine. 2009. 10. 033
63. Intanza-Seasonal Influenza Vaccine For Intradermal Use-NHS July 2012 http://hertsvalleysccg. nhs. uk/ uploads/file/Pharmacy/Local%20Decisions/Intanza% 20intradermal%20influenza%20vaccine%20201207 (HMMC). pdf
64. Puig-Barberà J, Natividad-Sancho A, Calabuig-Pérez J, Lluch-Rodrigo JA, Pastor-Villalba E, Martínez-Úbeda S, Díez-Domingo J. Intradermal and virosomal influenza vaccines for preventing influenza hospitalization in the elderly during the 2011-2012 influenza season: A comparative effectiveness study using the Valencia health care information system. Vaccine 2014; 32:5447-54; http://dx. doi. org/ 10. 1016/j. vaccine. 2014. 07. 095
65. Filippelli M., Lionetti E., Gennaro A., Lanzafame A., Arrigo T., Salpietro C., La Rosa M., Salvatore L. Hepatitis B vaccine by intradermal route in non responder patients: An update. World J Gastroenterol 2014; 20 (30):10383-94
66. Launay O, Van der Vliet D, Rosenberg AR, Michel ML, Piroth L, Rey D, de Verdière NC, Slama L, Martin K, Lortholary O, et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard Hepatitis B vaccine regimen in adults with HIV-1. JAMA 2011; 305:1432-40; PMID:21486976; http://dx. doi. org/10. 1001/ jama. 2011. 351
67. Fabrizi F, Dixit V, Messa P, Martin P. Intradermal vs intramuscular vaccine against hepatitis B infection in dialysis patients: A meta-analysis of randomized trials. J Viral Hepat 2011; 18:730-7; PMID:20819147; http://dx. doi. org/10. 1111/j. 1365-2893. 2010. 01354. x
68. Marra F, Young F, Richardson K, Marra CA. A metaanalysis of intradermal versus intramuscular influenza vaccines: immunogenicity and adverse events. Influenza Other Respir Viruses 2013; 7:584-603; PMID:2297417410. 1111/irv. 12000
69. Kis EE, Winter G, Myschik J. Devices for intradermal vaccination. Vaccine 2012; 30:523-38; http://dx. doi. org/10. 1016/j. vaccine. 2011. 11. 020
70. Auewarakul P, Kositanont U, Sornsathapornkul P, Tothong P, Kanyok R, Thongcharoen P. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine 2007; 25:659-63; PMID:17011678; http://dx. doi. org/10. 1016/j. vaccine. 2006. 08. 026
71. Brown H, Kasel JA, Freeman DM, Moise LD, Grose NP, Couch RB. The immunizing effect of influenza A/New Jersey/76 (Hsw1N1) virus vaccine administered intradermally and intramuscularly to adults. J Infect Dis 1977; 136: S466-S471; PMID:606768; http://dx. doi. org/10. 1093/infdis/136. Supplement_3. S466
72. Chiu SS, Peiris JS, Chan KH, Wong WH, Lau YL. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children. Pediatrics 2007; 119:1076-108; PMID:17545373; http://dx. doi. org/10. 1542/peds. 2006-3176
73. Halperin W, Weiss WI, Altman R, Diamond MA, Black KJ, Iaci AW, Black HC, Goldfield M. A comparison of the intradermal and subcutaneous routes of influenza vaccination with A/New Jersey/76 (swine flu) and A/Victoria/75: Report of a study and review of the literature. Am J Public Health 1979; 69:1247- 51; PMID:507256; http://dx. doi. org/10. 2105/ AJPH. 69. 12. 1247
74. Herbert FA, Larke RP, Markstad EL. Comparison of responses to influenza A/New Jersey/76-A/Victoria/75 virus vaccine administered intradermally or subcutaneously to adults with chronic respiratory disease. J Infect Dis 1979; 140:234-8; PMID:479641; http:// dx. doi. org/10. 1093/infdis/140. 2. 234b
75. Samuel BU, Cherian T, Sridharan G, Mukundan P, John TJ. Immune response to intradermally injected inactivated poliovirus vaccine. Lancet 1991; 338:343- 4; PMID:1677699; http://dx. doi. org/10. 1016/0140- 6736(91)90480-D
76. Samuel BU, Cherian T, Rajasingh J, Raghupathy P, John TJ. Immune response of infants to inactivated poliovirus vaccine injected intradermally. Vaccine 1992; 10:135; PMID:1311491; http://dx. doi. org/ 10. 1016/0264-410X(92)90039-M
77. Laurent PE, Bourhy H, Fantino M, Alchas P, Mikszta JA. Safety and efficacy of novel dermal and epidermal microneedle delivery systems for rabies vaccination in healthy adults. Vaccine 2010; 28:5850-6; PMID:20600481; http://dx. doi. org/10. 1016/j. vaccine. 2010. 06. 062
78. Mikszta JA, Dekker JP III, Harvey NG, Dean CH, Brittingham JM, Huang J, Sullivan VJ, Dyas B, Roy CJ, Ulrich RG. Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine. Infect Immun 2006; 74:6806-10; PMID:17030580; http://dx. doi. org/10. 1128/ IAI. 01210-06
79. McAllister DV, Wang PM, Davis SP, Park J-H, Canatella PJ, Allen MG, Prausnitz MR. Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: Fabrication methods and transport studies. PNAS 2003; 100:13755-60; PMID:14623977; http://dx. doi. org/10. 1073/ pnas. 2331316100
80. Wang PM, Cornwell M, Hill J, Prausnitz MR. Precise microinjection into skin using hollow microneedles. J Invest Dermatol 2006; 126:1080-7; PMID:16484988; http://dx. doi. org/10. 1038/sj. jid. 5700150
81. Daugimont L, Baron N, Vandermeulen G, Pavselj N, Miklavcic D, Jullien MC, Cabodevila G, Mir LM, Préat V. Hollow microneedle arrays for intradermal drug delivery and DNA electroporation. J Membr Biol 2010; 236:117-25; PMID:20652559; http://dx. doi. org/10. 1007/s00232-010-9283-0
82. Prausnitz MR. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev 2004; 56:581-7; http:// dx. doi. org/10. 1016/j. addr. 2003. 10. 023
83. Vrdoljak A. Review of recent literature on microneedle vaccine delivery technologies. Vaccine 2013; 3:47-55; http://dx. doi. org/10. 2147/VDT. S34682
84. Pokorná D, Poláková I, Kindlová M, Dusková M, Ludvíková V, Gabriel P, Kutinová L, Müller M, Šmahel M. Vaccination with human papillomavirus type 16-derived peptides using a tattoo device. Vaccine 2009; 27:3519-29; PMID:19464530; http://dx. doi. org/10. 1016/j. vaccine. 2009. 03. 073
85. Pokorna D, Rubio I, Muller M. DNA-vaccination via tattooing induces stronger humoral and cellular immune responses than intramuscular delivery supported by molecular adjuvants. Genet Vaccines 2008; 6:4; PMID:18257910; http://dx. doi. org/10. 1186/ 1479-0556-6-4
86. Van den Berg JH, Nuijen B, Beijnen JH, Vincent A, van Tinteren H, Kluge Jr, Woerdeman LA, Hennink WE, Storm G, Schumacher TN et al. Optimization of intradermal vaccination by DNA tattooing in human skin. Hum Gene Ther 2009; 20:181-9; PMID:19301471; http://dx. doi. org/10. 1089/ hgt. 2008. 073
87. Ciernik IF, Krayenbühl BH, Carbone DP. Puncturemediated gene transfer to the skin. Hum Gene Ther 1996; 7:893-9; PMID:8727503; http://dx. doi. org/ 10. 1089/hum. 1996. 7. 8-893
88. Bins AD, Jorritsma A, Wolkers MC, Hung CF, Wu TC, Schumacher TNM, Haanen JB. A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med 2005; 11:899-904; PMID:15965482; http://dx. doi. org/ 10. 1038/nm1264
89. Quaak SG, van den Berg JH, Oosterhuis K, Beijnen JH, Haanen JBAG, Nuijen B. DNA tattoo vaccination: effect on plasmid purity and transfection efficiency of different topoisoforms. J Control Release 2009; 139:153-9; PMID:19580829; http://dx. doi. org/10. 1016/j. jconrel. 2009. 06. 033
90. Ten Dam HG, Fillastre C, Conge G, Orssaud E, Gateff C, Tanaka A, Ramirez OO, Collas R, Wright J, Chambon L et al. The use of jet-injectors in BCG vaccination. Bull WHO 1970; 43:707-20. http:// www. ncbi. nlm. nih. gov/pmc/articles/PMC2427792/ pdf/bullwho00209-0064. pdf
91. Stanfield JP, Bracken PM, Waddell KM, Gall D. Diphtheria-Tetanus-Pertussis immunization by intradermal jet injection. Br Med J 1972; 2:197-9; PMID:5022729. http://www. ncbi. nlm. nih. gov/pmc/ articles/PMC1787936/pdf/brmedj02200-0029. pdf
92. Soonawala D, Verdijk P, Wijmenga-Monsuur AJ, Boog CJ, Koedam P, Visser LG, Rots NY. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine 2013; 31:3688-94; PMID:23770332; http:// dx. doi. org/10. 1016/j. vaccine. 2013. 05. 104
93. Dimache G1, Stoean C, Durbacǎ S, Croitoru M, Ionescu M, Nedelcu IN, Corbu I. Study of specific immune response to unadsorbed concentrated tetanus vaccine administered by intradermal route to nonimmunized persons in the last ten years. Arch Roum Pathol Exp Microbiol 1990; 49:51-62; PMID:2101203
94. Dimache G, Croitoru M, Dimache V, Cuteanu I, Vasilescu T. Lyophilized typhoid vaccine for intradermal use. J Biol Stand 1983; 11:261-9; PMID:6643508; http://dx. doi. org/10. 1016/S0092- 1157(83)80014-6
95. Dimache G, Croitoru M, Nicolae IN. Subcutaneous versus intradermal typhoid vaccination by "jet-injector" apparatus. Arch Roum Pathol Exp Microbiol 1982; 41:259-64; PMID:7159215
96. Dimache G, Dimache V, Ciudin L, Palade R, Croitoru M. Intradermal typhoid vaccination in men by jet-injector. Immunological estimation by laboratory tests. Arch Roum Pathol Exp Microbiol 1976; 36:227-32; PMID:617039
97. Bernard KW, Roberts MA, Sumner J, Winkler WG, Mallonee J, Baer GM, Chaney R. Human diploid cell rabies vaccine. Effectiveness of immunization with small intradermal or subcutaneous doses. JAMA 1982; 247:1138-42; PMID:7057603; http://dx. doi. org/10. 1001/jama. 1982. 03320330034022
98. McAllister L, Anderson J, Werth K, Cho I, Copeland K, Le Cam NB, Plant D, Mendelman PM, Cobb DK. Needle-free jet injection for administration of influenza vaccine: A randomised non-inferiority trial. Lancet 2014; 384:674-81; PMID:24881803; http:// dx. doi. org/10. 1016/S0140-6736(14)60524-9
99. Meyer Jr, HarryM, Daniel D. Hostetler Jr, BernheimBC, RogersNG, Lambin P, Chassary A, Labusquière R, Smadel JE. Response of Volta children to jet inoculation of combined live measles, smallpox and yellow fever vaccines. Bull World Health Organ 1964; 30:783-94; PMID:14215185. http://apps. who. int/iris/bitstream/ 10665/73714/1/bulletin_1964_30%286%29_783-794. pdf?ua=1
100. Kendall MAF. Needle-free vaccine injection. Drug Delivery Handbook Exp Pharmacol 2010; 197:193- 219; http://dx. doi. org/10. 1007/978-3-642-00477-3_7
101. Norman JJ, Arya JM, McClain MA, Frew PM, Meltzer MI, Prausnitz MR. Microneedle patches: Usability and acceptability for self-vaccination against influenza. Vaccine 2014; 32:1856-62; PMID:24530146; http:// dx. doi. org/10. 1016/j. vaccine. 2014. 01. 076
102. Leroux-Roels I, Weber F. Intanza® 9 μg intradermal seasonal influenza vaccine for adults 18 to 59 years of age. Hum Vaccines Immunother 2013; 9:115-21; PMID:23442585; http://dx. doi. org/10. 4161/ hv. 22342
103. Eizenberg P, Booy R, Naser N, Mason G, Stamboulian D, Weber F. Acceptance of Intanza® 9 μg intradermal influenza vaccine in routine clinical practice in Australia and Argentina. Adv Ther 2011; 28:640-9; PMID:21751080; http://dx. doi. org/10. 1007/s12325- 011-0042-0
104. Prymula R, Usluer G, Altinel S, Sichova R, Weber F. Acceptance and opinions of Intanza/IDflu intradermal influenza vaccine in the Czech Republic and Turkey. Adv Ther 2012; 29:41-52; PMID:22228256; http:// dx. doi. org/10. 1007/s12325-011-0090-5
105. Gardeniers HJ, Luttge R, Berenschot EJ, De Boer MJ, Yeshurun SY, Hefetz M, van den Berg A. Silicon micromachined hollow microneedles for transdermal liquid transport. J Microelectromech Syst 2003; 12:855-62; http://dx. doi. org/10. 1109/JMEMS. 2003. 820293
106. Rebeiz GM. RF MEMS: Theory, Design, and Technology. John Wiley & Sons 2004
107. Nadim Maluf and Kirt Williams. An Introduction to Microelectromechanical Systems Engineering, Second Edition Hardcover - June 30, 2004.
108. Della Cioppa G, Nicolay U, Lindert K, Leroux-Roels G, Clement F, Castellino F, Galli G1, Groth N, Levin Y, Del Giudice G. A dose-range study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration. Hum Vaccines Immunother 2014; 10:6, 1-10; PMID:24732325; http://dx. doi. org/10. 4161/hv. 28618
109. Hung IF, Levin Y, To KK, Chan KH, Zhang AJ, Li P, Li C, Xu T, Wong TY, Yuen KY. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. Vaccine 2012; 30:6427-35; PMID:22910287; http://dx. doi. org/10. 1016/j. vaccine. 2012. 08. 014
110. Rappuoli R, Mandl CW, Black S, De Gregorio E. Vaccines for the twenty-first century society. Nat Rev Immunol 2011; 11:865-72; http://dx. doi. org/ 10. 1038/nri3085
111. Chiu SS, Chan KH. Tu W, Lau YL, Peiris JS. Immunogenicity and safety of intradermal versus intramuscular route of influenza immunization in infants less than 6 months of age: A randomized controlled trial. Vaccine 2009; 27:4834-9; PMID:19523908; http:// dx. doi. org/10. 1016/j. vaccine. 2009. 05. 066
112. Ploin D, Schwarzenbach F, Dubray C, Nicolas JF, Goujon C, Trong MD, Laurent PE. Echographic measurement of skin thickness in sites suitable for intradermal vaccine injection in infants and children. Vaccine 2011; 29:8438-42; PMID:21821081; http:// dx. doi. org/10. 1016/j. vaccine. 2011. 07. 111
113. Stephany Troy et al. Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV-Infected Adults. JID Advance Access published January 28, 2015; http://jid. oxfordjournals. org/content/early/2015/01/07/infdis. jiu841. full. pdf +html
114. A new immunotherapy developed by the UK Company Circassia has the potential to make cat allergies an easily treatable condition. Human Vaccines Immunother 2013; 9:941-4; http://dx. doi. org/ 10. 4161/hv. 25213
115. Riedmann E. A vaccine for long-suffering cat allergy patients. Human Vaccines & Immunotherapeutics: News. Hum Vaccines Immunother 2013, 9:5, 941- 944, DOI: 10. 4161/hv. 25213
116. Investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoints in MAGRIT, a phase III non-small cell lung cancer clinical trial. Issued: Thursday 20 March 2014, London UK; Retrieved June 23, 2014: http://www. gsk. com/media/press-releases/2014/investigational-MAGEA3- antigen-specific-cancer-immunotherapeutic-doesnot- meet-first-co-primary-endpoints-in-MAGRIT. html
117. Tyagi P, Beloo M. MAGRIT: The largest-ever phase III lung cancer trial aims to establish a novel tumorspecific approach to therapy. Clin Lung Cancer 2009; 10:371-4; PMID:19808198; http://dx. doi. org/ 10. 3816/CLC. 2009. n. 052
118. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973; 137:1142-62; PMID:4573839; http://dx. doi. org/10. 1084/jem. 137. 5. 1142
119. Glenn GM, Kenney RT. Mass vaccination: Solutions in the skin. Curr Top Microbiol Immunol 2006; 304:247-68; PMID:16989274; http://dx. doi. org/ 10. 1007/3-540-36583-4_14
120. Couzin-Frankel. Cancer immunotherapy. Science 2013; 342:1432-3; http://dx. doi. org/10. 1126/ science. 342. 6165. 1432